Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gastrointestinal 1

Conditions

Sarcoma 5Histiocytoma, Malignant Fibrous 4Gastrointestinal Stromal Tumors 4Osteosarcoma 2Neoplasm Metastasis 2Melanoma 2Liposarcoma 2Gliosarcoma 2Bone Neoplasms 2Vulvar Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Somatostatinoma 1Seminoma 1Sarcoma, Kaposi 1Rhabdomyosarcoma 1Rare Diseases 1Pseudomyxoma Peritonei 1Pheochromocytoma 1Perivascular Epithelioid Cell Neoplasms 1Parathyroid Neoplasms 1Paranasal Sinus Neoplasms 1Paraganglioma 1Paget Disease, Extramammary 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Nasopharyngeal Carcinoma 1

Interventions

Doxorubicin 11Zidovudine 9Vincristine 8Bleomycin 7Liposomes 5Interferon alpha-2 5tecogalan 4Etoposide 4Specimen Handling 3Magnetic Resonance Spectroscopy 3Biopsy 3sargramostim 2interferon alfa-n1 2Semaxinib 2Rituximab 2Ritonavir 2Polymerase Chain Reaction 2Nivolumab 2Mitoxantrone 2Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination 2Didanosine 2Alitretinoin 2vesnarinone 1tin etiopurpurin 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1pembrolizumab 1nirogacestat 1fludarabine phosphate 1emvododstat 1efineptakin alfa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HIV Infections × CTLA-4 Antigen × Sarcoma × Clear all
NCT02408861 2026-01-21

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Terminated
79 enrolled 24 charts
GastrointestinalSarcomaThoracic

Anus Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Sarcoma, Kaposi, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡